TABLE 5

Composition of placebo and GI.1/GII.4 bivalent VLP vaccine formulations per 0.5 ml

GroupNo. of participantsAmt of GI.1 VLPs (μg)Amt of GII.4 VLPs (μg)Total amt of VLPs/dose (μg)Amt of MPL (μg)Amt of Al(OH)3 (mg)
Placebo800000
5/5 μg VLP vaccine105510500.5
15/15 μg VLP vaccine9151530500.5
50/50 μg VLP vaccine95050100500.5
150/150 μg VLP vaccine6150150300500.5